Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07106762 · ClinicalTrials.gov registry record · Phase 2

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

A Phase 2 study of Urothelial Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 2
Development phase
470
Enrollment target
20
Study locations

NCT07106762 is a Phase 2 study of Urothelial Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 470 participants, below the 556-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07106762, a Phase 2 study of Urothelial Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 2
Development phase
470 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

Conditions Studied

Urothelial Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Gemcitabine
  • DRUG Iza-bren

Study Locations (20)

California

  • Local Institution - 0162 - Fullerton
  • Local Institution - 0252 - Palo Alto
  • Local Institution - 0163 - Sacramento
  • Local Institution - 0139 - Sacramento
  • Local Institution - 0251 - San Francisco
  • Local Institution - 0254 - Santa Rosa

New York

  • Local Institution - 0248 - Buffalo
  • Icahn School of Medicine at Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Colorado

  • Local Institution - 0245 - Dillon
  • Shaw Cancer Center - Edwards

Ohio

  • Fairview Hospital - Cleveland
  • Cleveland Clinic - Cleveland

Arizona

  • Local Institution - 0167 - Gilbert

District of Columbia

  • Local Institution - 0250 - Washington D.C.

Florida

  • Local Institution - 0247 - Miami

Kentucky

  • Local Institution - 0193 - Lexington

Trial Details

FieldValue
Enrollment Target 470 participants
Start Date 2025-09-30
Est. Completion 2033-11-18
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07106762

The ClinicalTrials.gov registry entry for NCT07106762 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 556-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (15% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT07106762 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Colorado.

Frequently Asked Questions

What is clinical trial NCT07106762 about?

NCT07106762 is a clinical study titled "Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy". A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

What is the current status of trial NCT07106762?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 470 participants. The study started on 2025-09-30. Estimated completion is 2033-11-18.

What conditions does trial NCT07106762 study?

This clinical trial studies the following conditions: Urothelial Cancer.

What interventions are being tested in trial NCT07106762?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Iza-bren (DRUG).

Who is sponsoring clinical trial NCT07106762?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07106762 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urothelial Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.